抗肿瘤血管生成药物不良反应的发生机制及处理

Pathogenesis and Treatment Principle of Adverse Reactions of Anti-angiogenetic Drugs

血管生成是恶性肿瘤发生、发展及转移的重要机制之一,抗血管生成治疗是肿瘤分子靶向治疗的重要策略。目前常用的治疗药物主要包括以贝伐单抗为代表的单克隆抗体类,以索拉菲尼、舒尼替尼、阿帕替尼等为代表的酪氨酸激酶抑制剂类,以及部分中药。不同种类药物的不良反应及其发生率不同,了解药物不良反应的发生机制及处理原则,将会提高患者用药的耐受性及改善预后。

Angiogenesis plays a very important role in tumor pathogenesis, development and metastasis. Inhibiting angiogenesis has become a successful strategy in tumor molecular-targeting therapy. The anti-angio- genic drugs mainly include the monoclonal antibody like bevacizumab and the tyrosine kinase inhibitors such as serafanib, sunitinib and apatinib. Some Chinese medical herbs are also used as anti-angiogenic drugs. How- ever, different kinds of anti-angiogenie drugs have different adverse effects and different incidences. It＇s important to know the adverse effects and the corresponding principle of treatment, which will improve the patient＇s tolerance and prognosis.